---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-127041"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:36:23.816790+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# GLOW2 Phase 3 positive: Zenkuda meets primary endpoint, 62.5% vs 3.3% DRSS improvement, BLA accelerated

## Summary
- 62.5% of Zenkuda patients achieved ≥2-step DRSS improvement vs 3.3% sham (p<0.0001).
- 85% risk reduction in sight-threatening complications (2.4% vs 15.8%, p=0.0001); 13.7% had ≥3-step DRSS improvement vs 0% sham.
- Zenkuda well-tolerated: 0% intraocular inflammation, low cataract rate (2.3% vs 1.6%).
- Efficacy independent of GLP-1 use: 60.0% with GLP-1 vs 64.3% without GLP-1.
- Kodiak intends to accelerate BLA for Zenkuda; KSI-501 (wet AMD) readout 3Q2026, KSI-101 (MESI) 4Q2026.

## SEC filing metadata
- accession: 0001193125-26-127041
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000119312526127041/0001193125-26-127041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000119312526127041/d283186d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-127041
- JSON: https://secwatch.observer/filing/0001193125-26-127041.json
- Plain text: https://secwatch.observer/filing/0001193125-26-127041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.